S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
S&P 500   5,251.79 (+0.06%)
DOW   39,784.74 (+0.06%)
QQQ   444.89 (+0.01%)
AAPL   171.06 (-1.30%)
MSFT   420.83 (-0.14%)
META   487.19 (-1.35%)
GOOGL   150.43 (-0.29%)
AMZN   180.40 (+0.32%)
TSLA   176.87 (-1.65%)
NVDA   906.94 (+0.49%)
NIO   4.64 (-0.64%)
AMD   182.13 (+1.41%)
BABA   72.47 (+1.23%)
T   17.58 (+0.17%)
F   13.27 (+1.61%)
MU   118.46 (-0.57%)
CGC   9.66 (+1.15%)
GE   175.21 (-2.73%)
DIS   122.97 (+1.64%)
AMC   3.69 (-14.98%)
PFE   27.90 (+0.43%)
PYPL   66.95 (+0.57%)
XOM   115.66 (+0.60%)
NASDAQ:IVVD

Invivyd (IVVD) Stock Price, News & Analysis

$4.23
+0.23 (+5.75%)
(As of 11:57 AM ET)
Today's Range
$3.96
$4.40
50-Day Range
$3.09
$5.04
52-Week Range
$0.98
$5.20
Volume
589,749 shs
Average Volume
785,293 shs
Market Capitalization
$465.77 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50

Invivyd MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
194.1% Upside
$12.50 Price Target
Short Interest
Healthy
2.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Invivyd in the last 14 days
Based on 21 Articles This Week
Insider Trading
Selling Shares
$19.75 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($0.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.53 out of 5 stars

Medical Sector

291st out of 939 stocks

Biological Products, Except Diagnostic Industry

40th out of 154 stocks

IVVD stock logo

About Invivyd Stock (NASDAQ:IVVD)

Invivyd, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2. It also has discovery stage candidates for the prevention of seasonal influenza. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

IVVD Stock Price History

IVVD Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Invivyd (NASDAQ:IVVD) Given "Buy" Rating at HC Wainwright
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Ligand Pharmaceuticals Incorporated
Invivyd Stock (NASDAQ:IVVD), Short Interest Report
Invivyd Refiles Financials Citing Viability Concerns
When Will Invivyd, Inc. (NASDAQ:IVVD) Become Profitable?
See More Headlines
Receive IVVD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invivyd and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IVVD
Fax
N/A
Employees
84
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.50
High Stock Price Target
$15.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+194.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-241,320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.27 per share

Miscellaneous

Free Float
89,083,000
Market Cap
$467.97 million
Optionable
Optionable
Beta
0.60
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. David Hering M.B.A. (Age 48)
    CEO & Director
    Comp: $932.5k
  • Ms. Jill Andersen J.D. (Age 51)
    Chief Legal Officer & Corporate Secretary
    Comp: $619.33k
  • Mr. William E. Duke Jr. (Age 52)
    M.B.A., Chief Financial Officer
  • Mr. Jeremy Gowler (Age 47)
    Chief Operating Officer & Chief Commercial Officer
  • Ms. Stacy Price M.S. (Age 55)
    Chief Technology & Manufacturing Officer
  • Dr. Robert D. Allen Ph.D.
    Chief Scientific Officer
  • Ms. Julie Green M.B.A.
    Chief Human Resources Officer
  • Dr. Peter C. Schmidt M.D. (Age 43)
    M.S., M.Sc., Chief Medical Officer
  • Ms. Heidi Spurling M.S.
    VP of Strategy & Operations and Chief of Staff to the CEO

IVVD Stock Analysis - Frequently Asked Questions

Should I buy or sell Invivyd stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Invivyd in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IVVD shares.
View IVVD analyst ratings
or view top-rated stocks.

What is Invivyd's stock price target for 2024?

2 brokerages have issued 12-month price targets for Invivyd's stock. Their IVVD share price targets range from $10.00 to $15.00. On average, they anticipate the company's stock price to reach $12.50 in the next year. This suggests a possible upside of 194.1% from the stock's current price.
View analysts price targets for IVVD
or view top-rated stocks among Wall Street analysts.

How have IVVD shares performed in 2024?

Invivyd's stock was trading at $3.94 at the start of the year. Since then, IVVD stock has increased by 7.9% and is now trading at $4.25.
View the best growth stocks for 2024 here
.

Are investors shorting Invivyd?

Invivyd saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 1,640,000 shares, a drop of 14.1% from the February 29th total of 1,910,000 shares. Based on an average daily volume of 760,200 shares, the short-interest ratio is currently 2.2 days. Currently, 2.9% of the company's shares are sold short.
View Invivyd's Short Interest
.

When is Invivyd's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our IVVD earnings forecast
.

What ETF holds Invivyd's stock?

Amplify Treatments, Testing and Advancements ETF holds 30,909 shares of IVVD stock, representing 0.32% of its portfolio.

Who are Invivyd's major shareholders?

Invivyd's stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.28%), Vanguard Group Inc. (2.28%), Bridgeway Capital Management LLC (0.46%), Charles Schwab Investment Management Inc. (0.28%), Balyasny Asset Management L.P. (0.08%) and a16z Perennial Management L.P. (0.07%).
View institutional ownership trends
.

How do I buy shares of Invivyd?

Shares of IVVD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IVVD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners